Compare Sea Limited (SE) vs 10X Genomics Inc (TXG) Price & Performance

Sea Limited (SE) trades at $113.33, up 1.11% with bullish technical signals and strong analyst support. The company shows robust revenue growth from $16.8B in 2024 to $22.9B in 2025, with net income reaching $1.58B. Recent earnings beat expectations in Q1 and Q2 2026, while operating cash flow improved significantly to $5.02B in 2025. Technical indicators show bullish moving averages with support at $111 and resistance at $115.

SE presents a compelling growth story with expanding profitability and positive cash flow generation. However, elevated valuation multiples (P/E 43.76) and insider selling activity warrant caution. The consensus price target of $143.67 suggests 27% upside potential, but investors should monitor competitive pressures in Southeast Asian markets and execution risks as the company scales.

TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.

The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.